A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, including measuring body fat to diagnose obesity instead of BMI alone.The co

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new rule that would expand Medicare and Medicaid coverage for enrollees seeking prescription drugs popularized in recent years as weight-loss expedients.

A coalition of obesity-related patient advocacy groups is calling on the incoming Trump administration to finalize a proposal that would allow Medicare to cover obesity medications. Led by

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment. The Wednesday statement from the Centers for Medicare & Medicaid Services comes after Zepbound in December became the first drug approved in the U.

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden leaving 11th-hour health measures for TrumpThe Biden administration in its final days has been

Wegovy, Ozempic, and other weight loss drugs have drastically changed the treatment of obesity, but consumers have complained about high out-of-pocket prices. Medicare does not cover the two ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.